Evidence map›Paper›PMID 25750919›Full record

ArticleAnnals of clinical and translational neurology2015

Visual pathway neurodegeneration winged by mitochondrial dysfunction.

Axel Petzold, Philip G Nijland, Lisanne J Balk, Angela Maria Amorini, Giacomo Lazzarino, Mike P Wattjes, Claudio Gasperini, Paul van der Valk, Barbara Tavazzi, Giuseppe Lazzarino and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Axel PetzoldDepartment of Neurology, VU University Medical Center De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands ; Department of Ophthalmology, VU University Medical Center De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands ; Molecular Neuroscience, UCL Institute of Neurology Queen Square, London, WC1N 3BG, United Kingdom ; Moorfields Eye Hospital, Neuro-ophthalmology City Road, London, UK.
Philip G NijlandDepartment of Pathology, VU University Medical Center Amsterdam, The Netherlands.
Lisanne J BalkDepartment of Neurology, VU University Medical Center De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Angela Maria AmoriniInstitute of Biochemistry and Clinical Biochemistry, Catholic University of Rome Largo F. Vito 1, 00168, Rome, Italy.
Giacomo LazzarinoInstitute of Biochemistry and Clinical Biochemistry, Catholic University of Rome Largo F. Vito 1, 00168, Rome, Italy.
Mike P WattjesDepartment of Radiology & Nuclear Medicine, VU University Medical Center Amsterdam, The Netherlands.
Claudio GasperiniDepartment of Neurosciences, S Camillo Forlanini Hospital Circonvallazione Gianicolense 87, 00152, Rome, Italy.
Paul van der ValkDepartment of Pathology, VU University Medical Center Amsterdam, The Netherlands.
Barbara TavazziInstitute of Biochemistry and Clinical Biochemistry, Catholic University of Rome Largo F. Vito 1, 00168, Rome, Italy.
Giuseppe LazzarinoDivision of Biochemistry and Molecular Biology, Department of Biology, Geology and Environmental Sciences, University of Catania Viale A. Doria 6, 95125, Catania, Italy.
Jack van HorssenMolecular Cell Biology and Immunology, VU University Medical Center Amsterdam, The Netherlands.
Amsterdam UMC Location Vrije Universiteit Amsterdam · NLUniversità Cattolica del Sacro Cuore · ITCarlo Forlanini Hospital · ITMoorfields Eye Hospital NHS Foundation Trust · GBUniversity of Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo test for structural and functional contribution of mitochondrial dysfunction to neurodegeneration in multiple sclerosis (MS). A visual pathway model void of MS lesions was chosen in order to exclude neurodegeneration secondary to lesion related axonotmesis.

methodsA single-centre cohort study (230 MS patients, 63 controls). Spectral domain optical coherence tomography of the retina, 3T magnetic resonance imaging of the brain, spectrophotometric assessment of serum lactate levels. Postmortem immunohistochemistry.

resultsThe visual pathway was void of MS lesions in 31 patients and 31 age-matched controls. Serum lactate was higher in MS compared to controls (P = 0.029). High serum lactate was structurally related to atrophy of the retinal nerve fiber layer at the optic disc (P = 0.041), macula (P = 0.025), and the macular ganglion cell complex (P = 0.041). High serum lactate was functionally related to poor color vision (P < 0.01), Expanded Disability Status Scale score (R = 0.37, P = 0.041), Guy's Neurological disability score (R = 0.38, P = 0.037), MS walking scale (R = 0.50, P = 0.009), upper limb motor function (R = 0.53, P = 0.002). Immunohistochemistry demonstrated increased astrocytic expression of a key lactate generating enzyme in MS lesions as well as profound vascular expression of monocarboxylate transporter-1, which is involved in lactate transport.

interpretationThis study provides structural, functional, and translational evidence for visual pathway neurodegeneration in MS related to mitochondrial dysfunction.

Identifiers

PMID25750919
PMCPMC4338955
OpenAlexW2074464138

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.